Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Determinants of response and resistance to CAR T cell therapy.

Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.

Semin Cancer Biol. 2019 Nov 6. pii: S1044-579X(19)30219-6. doi: 10.1016/j.semcancer.2019.11.004. [Epub ahead of print] Review.

PMID:
31705998
2.

[Immuno-Oncology Meets Intensive Care Medicine: CAR-T cells].

Böll B, Borrega JG, Schellongowski P, Subklewe M, von Bergwelt-Baildon M.

Dtsch Med Wochenschr. 2019 Sep;144(19):1342-1347. doi: 10.1055/a-0853-4689. Epub 2019 Sep 26. German.

PMID:
31559615
3.

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.

Blood Adv. 2019 Sep 24;3(18):2696-2699. doi: 10.1182/bloodadvances.2019000265. No abstract available.

4.

Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.

Subklewe M, von Bergwelt-Baildon M, Humpe A.

Transfus Med Hemother. 2019 Feb;46(1):15-24. doi: 10.1159/000496870. Epub 2019 Feb 5. Review.

5.

Advances in cancer immunotherapy 2019 - latest trends.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.

J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review.

6.

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.

Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.

J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review.

7.

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.

Köhnke T, Bücklein V, Rechkemmer S, Schneider S, Rothenberg-Thurley M, Metzeler KH, Sauerland MC, Hiddemann W, Spiekermann K, Subklewe M.

Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4. No abstract available.

8.

Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.

Thaler FS, Thaller AL, Biljecki M, Schuh E, Winklmeier S, Mahler CF, Gerhards R, Völk S, Schnorfeil F, Subklewe M, Hohlfeld R, Kümpfel T, Meinl E.

Ann Neurol. 2019 Mar;85(3):448-454. doi: 10.1002/ana.25414. Epub 2019 Jan 28.

PMID:
30635933
9.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

10.

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.

Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.

PMID:
30275109
11.

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.

Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.

Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018.

12.

[Challenges in Immuno-Oncology - Possibilities for Optimization].

Shimabukuro-Vornhagen A, Subklewe M, von Bergwelt-Baildon M.

Dtsch Med Wochenschr. 2018 Jul;143(14):1022-1029. doi: 10.1055/a-0549-6987. Epub 2018 Jul 13. German.

PMID:
30005436
13.

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.

Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26.

14.

Cytokine release syndrome.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS.

J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. Review.

15.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

16.

Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.

Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.

Transplantation. 2018 Nov;102(11):1914-1923. doi: 10.1097/TP.0000000000002269.

PMID:
29757894
17.

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.

Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. eCollection 2018.

18.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

19.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. [Epub ahead of print]

PMID:
29249818
20.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

21.

End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.

Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU.

Transplantation. 2018 May;102(5):868-875. doi: 10.1097/TP.0000000000002006.

PMID:
29189632
22.

The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.

Gaidt MM, Ebert TS, Chauhan D, Ramshorn K, Pinci F, Zuber S, O'Duill F, Schmid-Burgk JL, Hoss F, Buhmann R, Wittmann G, Latz E, Subklewe M, Hornung V.

Cell. 2017 Nov 16;171(5):1110-1124.e18. doi: 10.1016/j.cell.2017.09.039. Epub 2017 Oct 12.

23.

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Dörfel D, Salih HR, Jung G, Nößner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA.

Leukemia. 2018 Feb;32(2):313-322. doi: 10.1038/leu.2017.257. Epub 2017 Aug 14.

24.

Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.

Köhnke T, Wittmann VK, Bücklein VL, Lichtenegger F, Pasalic Z, Hiddemann W, Spiekermann K, Subklewe M.

Br J Haematol. 2017 Nov;179(3):480-487. doi: 10.1111/bjh.14901. Epub 2017 Aug 18.

PMID:
28832948
25.

Recent developments in immunotherapy of acute myeloid leukemia.

Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M.

J Hematol Oncol. 2017 Jul 25;10(1):142. doi: 10.1186/s13045-017-0505-0. Review.

26.

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.

Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. Epub 2017 May 19.

PMID:
28420034
27.

Targeting CD157 in AML using a novel, Fc-engineered antibody construct.

Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.

Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060.

28.

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.

Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.

Oncotarget. 2017 Feb 14;8(7):11284-11301. doi: 10.18632/oncotarget.14500.

29.

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.

J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19.

PMID:
27992268
30.

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.

Bücklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.

Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421. eCollection 2016 Jul.

31.

Features of Human CD3+CD20+ T Cells.

Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M.

J Immunol. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089. Epub 2016 Jul 13.

32.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group.

Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10.

PMID:
27288520
33.

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U.

Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. Epub 2016 May 12.

34.

Immunotherapy in Tumors.

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review.

35.

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.

Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M.

J Hematol Oncol. 2015 Oct 8;8:111. doi: 10.1186/s13045-015-0213-6.

36.

RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.

Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M.

Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8. Epub 2015 Sep 16.

PMID:
26377688
37.

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4.

PMID:
26239198
38.

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M.

J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2.

39.

Immunotherapy for Acute Myeloid Leukemia.

Lichtenegger FS, Krupka C, Köhnke T, Subklewe M.

Semin Hematol. 2015 Jul;52(3):207-14. doi: 10.1053/j.seminhematol.2015.03.006. Epub 2015 Mar 17. Review.

PMID:
26111468
40.

Bendamustine and the immune system: a wolf in sheep's clothing?

Dreyling M, Subklewe M.

Leuk Lymphoma. 2015 Apr;56(4):837-8. doi: 10.3109/10428194.2015.1024942. No abstract available.

PMID:
25926137
41.

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

Zugmaier G, Klinger M, Schmidt M, Subklewe M.

Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13. Review.

PMID:
25883042
42.

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.

Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I.

PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. eCollection 2015.

43.

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.

Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17.

PMID:
25322685
44.

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.

Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.

Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Epub 2014 Sep 4. Review.

PMID:
25186611
45.

Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML.

Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M.

Leuk Res. 2014 Aug;38(8):964-9. doi: 10.1016/j.leukres.2014.05.014. Epub 2014 Jun 2.

PMID:
24957413
46.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.

PMID:
24912430
47.

Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A.

Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. Epub 2014 Apr 3.

48.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9.

49.

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.

PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. eCollection 2014.

50.

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A.

ACS Chem Biol. 2014 Mar 21;9(3):802-11. doi: 10.1021/cb400728e. Epub 2014 Jan 17.

Supplemental Content

Loading ...
Support Center